Selective use of abciximab in coronary stenting: overall outcomes can still be equivalent to those in the EPISTENT treatment group.
Int J Cardiovasc Intervent. 2001 Mar;4(1):15-20. doi: 10.1080/146288401316922643.
Int J Cardiovasc Intervent. 2001.
PMID: 12431335